Questions in the dark
CJC-1295 Ipamorelin FAQ
Direct answers, cited where the claim is quantitative — and no human dosing, on any question.
When is the best time to take CJC-1295 / Ipamorelin?
Research does not establish a human timing protocol, and none is given here. The mechanistic hint comes from sleep: intravenous ghrelin pulses increased slow-wave sleep and delta-wave activity in healthy men, linking ghrelin-receptor signalling — ipamorelin's target — to sleep architecture [8]. GH also naturally crests in deep sleep, which is why the pairing is so often discussed in a pre-sleep, nocturnal frame rather than at any clock time.
What is CJC-1295 / Ipamorelin good for?
In the literature, it raises growth hormone and IGF-1: a single subcutaneous CJC-1295 (DAC) dose lifted mean GH 2- to 10-fold for six or more days and IGF-1 for nine to eleven days in healthy adults [1]. People report deeper sleep, faster recovery, and gradual leaning-out, but those are anecdotal and not measured for the fixed blend. What it is good for in human outcomes remains uncertified for the combination.
What are the bad side effects of CJC-1295 and Ipamorelin?
Ipamorelin is the first selective GH secretagogue — unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol even at more than 200 times the GH-releasing dose [2], so the stress-hormone side effects of older peptides are largely absent. The class's chief metabolic concern is raised blood glucose from reduced insulin sensitivity [6]. People also report water retention, injection-site reactions, flushing, and carpal-tunnel-like tingling — fluid-related and anecdotal.
How long do CJC-1295 and Ipamorelin take to work?
On hormone levels, fast. A single subcutaneous dose of CJC-1295 (DAC) raised mean plasma GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for nine to eleven days in healthy adults, with IGF-1 above baseline up to 28 days after repeat dosing [1]. Ipamorelin's GH peak comes around forty minutes after a dose in rodents. Reported subjective effects like sleep are described within one to two weeks — but that is anecdote, not a measured timeline.
How many mg of CJC-1295 and Ipamorelin should I take?
No human dose is provided here, because none has been validated for this combination. Published figures are research parameters by species and route — for example, CJC-1295 (DAC) was studied at 30–90 µg/kg subcutaneously in human Phase 1 work [1], and ipamorelin at 100 µg/kg three times daily in rodent bone studies. These are study conditions, not a recommendation, and self-administration falls outside any tested protocol.
Does CJC-1295 raise testosterone?
The literature does not show CJC-1295 raising testosterone; it acts on the growth-hormone axis, not the gonadal one. A single subcutaneous CJC-1295 (DAC) dose raised GH 2- to 10-fold for six or more days and IGF-1 for nine to eleven days [1] — those are GH-axis effects. Any testosterone change is not an established finding for CJC-1295 in the cited record.
Does Ipamorelin reduce belly fat?
Not shown for ipamorelin directly. The relevant controlled evidence is for the GHRH analogue tesamorelin: a 2026 meta-analysis of five RCTs found significant visceral adipose tissue reduction (−27.71 cm²) and hepatic fat reduction (−4.28%) [7]. That is read-across for GH-axis stimulation, not a measurement of ipamorelin, whose human efficacy is unvalidated and largely preclinical [11].
What are the downsides to CJC-1295 / Ipamorelin?
The hard downside is the evidence gap: the fixed blend has never been tested in a controlled trial, neither peptide is FDA-approved, and research-grade material is of unverified purity. On effects, ipamorelin avoids the cortisol/ACTH rise of older GHRPs even far above the GH-releasing dose [2], but the class still carries a glucose/insulin-sensitivity signal [6], plus reported fluid retention and injection-site reactions.
Which is better, Sermorelin or Ipamorelin?
They do different jobs, so 'better' depends on the role. Sermorelin is a GHRH analogue (the accelerator the CJC-1295 arm also pushes); ipamorelin is a GHRP acting on the ghrelin receptor [2]. The synergy literature shows a GHRH plus a GHRP together release more GH than either class alone [3], so in practice they are treated as complementary halves rather than rivals.
Can you take both Sermorelin and Ipamorelin together?
The mechanistic rationale for combining a GHRH analogue with a GHRP is well established: in normal men, submaximal GHRP doses combined with GHRH stimulated GH release synergistically, the two acting through independent mechanisms [3]. That said, no controlled human trial validates a sermorelin-plus-ipamorelin protocol specifically, and no human dosing is provided here.
Is Tesamorelin better than Ipamorelin?
By weight of controlled evidence, tesamorelin has far more: a 2026 meta-analysis of five RCTs showed significant visceral- and hepatic-fat reduction, lean-mass gain, and raised IGF-1, with no serious adverse events [7]. Ipamorelin lacks any comparable human dataset and is largely preclinical [11]. 'Better' depends on the goal, but on human evidence depth, tesamorelin is the more studied of the two.
Is Ipamorelin stronger than Sermorelin?
They are not measured on a shared 'strength' scale, because they hit different receptors — ipamorelin the ghrelin receptor, sermorelin (like CJC-1295) the GHRH receptor [2]. Ipamorelin's notable property is selectivity: a full GH effect without the ACTH/cortisol rise of other GHRPs, even above 200 times the GH-releasing dose [2]. Combining the two classes, not ranking them, is what the synergy literature supports [3].
Which is safer, Sermorelin or Ipamorelin?
Neither has a controlled long-term safety database in this research-peptide context, so a clean ranking is not available. Ipamorelin's selectivity profile — no ACTH or cortisol rise even far above the GH-releasing dose [2] — is a favorable feature. Both share the GH-secretagogue class concern of raised blood glucose from reduced insulin sensitivity [6], and neither is FDA-approved.
What is CJC-1295 / Ipamorelin?
It is a research combination of two peptides: CJC-1295, a long-acting GHRH analogue, and ipamorelin, a selective ghrelin-receptor agonist (a GHRP) [2]. Used together they aim to raise the body's own growth-hormone pulse through two independent pathways. Neither is FDA-approved, and the fixed combination has never been studied in a controlled clinical trial — its case rests on single-component data and general synergy evidence.
How much CJC-1295 / Ipamorelin should I take?
No human amount is given here; none has been validated for the combination. The published numbers are research conditions by species and route — CJC-1295 (DAC) at 30–90 µg/kg subcutaneously in human Phase 1 studies [1], ipamorelin in milligram-per-kilogram rodent protocols. Those describe experiments, not a personal dose, and community self-administration sits outside any studied protocol.
Is CJC-1295 / Ipamorelin safe?
There is no controlled safety trial of the fixed blend, so 'safe' is not established for it. The class is generally well tolerated short-term, with raised blood glucose from reduced insulin sensitivity as the chief concern and long-term cancer/mortality data still needed [6]. Ipamorelin's selectivity (no cortisol/ACTH rise even far above its GH-releasing dose) is reassuring on one axis [2], but unverified purity and self-injection add real, unstudied risk.
Does CJC-1295 / Ipamorelin work?
It demonstrably raises GH and IGF-1 at the component level: a single CJC-1295 (DAC) dose lifted GH 2- to 10-fold for six or more days and IGF-1 for nine to eleven days in healthy adults [1], and ipamorelin releases GH selectively [2]. Whether that translates to the human body-composition or recovery outcomes people seek from the blend has not been measured in any controlled trial.
Is Ipamorelin FDA approved?
No. Ipamorelin is not approved by the FDA or any regulator for any human indication; it is sold only as a research chemical. A review of GH secretagogues frames the class as generally well tolerated but stresses unresolved long-term safety, including cancer-incidence and mortality data, and the chief concern of raised blood glucose [6]. CJC-1295 is likewise unapproved.
How to reconstitute CJC-1295 / Ipamorelin (5mg)?
No preparation instructions are provided here, as this is a research-literature digest, not a handling guide. In research context, lyophilised (freeze-dried) peptide is reconstituted with bacteriostatic water — sterile water with 0.9% benzyl alcohol — then kept refrigerated at 2–8 °C, where it degrades over weeks via deamidation. Mis-reconstitution and contamination are documented risks of community self-administration outside any studied protocol.
Where to inject CJC-1295 / Ipamorelin?
No injection-site guidance is given here. Research studies used subcutaneous and intravenous routes (and, for ipamorelin PK in rodents, intranasal and minipump infusion). Injection-site redness, itching, and mild swelling are among the most commonly reported community complaints — anecdotal — with site rotation the usual community suggestion; self-injection falls outside any tested protocol.
Does Ipamorelin make you hungry / increase appetite?
Plausibly, by mechanism, and commonly reported. Ipamorelin acts on the ghrelin receptor, and ghrelin is the body's hunger signal — so increased appetite in the hours after dosing is one of the more frequently reported effects, described as milder than with GHRP-6. The broader class is well tolerated overall, with raised blood glucose the chief noted concern [6]. The appetite report itself is anecdotal.
Can I take CJC-1295 / Ipamorelin in the morning?
No timing recommendation is given. The mechanistic pull is nocturnal: ghrelin signalling is tied to slow-wave sleep [8] and GH crests in deep sleep, which is why the pairing is usually framed around the sleeping pulse rather than the morning. Any clock-time choice in community use is not backed by a controlled human protocol for this combination.